EMA Ready To End Adaptive Pathways Pilot, Tap Into Lessons Learned
This article was originally published in The Pink Sheet Daily
Executive Summary
"Successful" pilot project supports integrating concepts into existing regulatory frameworks, EMA official who coordinated it says.
You may also be interested in...
'Different Animals With Different Purposes': Putting PRIME And Adaptive Pathways In Context
EMA official gives perspectives on how PRIME and adaptive pathways compare, and how they fit with other programs such as conditional authorization.
Adaptive Licensing: Industry On Board, With Caveats
The EU's adaptive licensing pilot project, which was launched in March 2014, is designed to deliver an early centralized marketing license for promising innovative therapies for patients with serious or life-threatening conditions. However, while the benefits are clear, there are a number of challenges that will need to be addressed.
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.